Skip to main content
eScholarship
Open Access Publications from the University of California

Targets for therapy in sarcomeric cardiomyopathies

  • Author(s): Tardiff, JC
  • Carrier, L
  • Bers, DM
  • Poggesi, C
  • Ferrantini, C
  • Coppini, R
  • Maier, LS
  • Ashrafian, H
  • Huke, S
  • Van Der Velden, J
  • et al.

Published Web Location

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4402369/
No data is associated with this publication.
Abstract

© 2015 Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2015. To date, no compounds or interventions exist that treat or prevent sarcomeric cardiomyopathies. Established therapies currently improve the outcome, but novel therapies may be able to more fundamentally affect the disease process and course. Investigations of the pathomechanisms are generating molecular insights that can be useful for the design of novel specific drugs suitable for clinical use. As perturbations in the heart are stage-specific, proper timing of drug treatment is essential to prevent initiation and progression of cardiac disease in mutation carrier individuals. In this review, we emphasize potential novel therapies which may prevent, delay, or even reverse hypertrophic cardiomyopathy caused by sarcomeric gene mutations. These include corrections of genetic defects, altered sarcomere function, perturbations in intracellular ion homeostasis, and impaired myocardial energetics.

Many UC-authored scholarly publications are freely available on this site because of the UC Academic Senate's Open Access Policy. Let us know how this access is important for you.

Item not freely available? Link broken?
Report a problem accessing this item